Posaconazole in immunocompromised pediatric patients

References

• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet. Oncol. 2014;15:e327–40.
   PubMed Web of Science ®Google Scholar
• Dornbusch HJ, Manzoni P, Roilides E, et al. Invasive fungal infections in children. The Pediatric Infectious Disease Journal. 2009;28:734–737.
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr. Blood Cancer. 2012;59:21–26.
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Dokos C, Lehrnbecher T, et al. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation. Drugs. 2012;72:685–704.
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197–205.
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286–94.
   PubMed Web of Science ®Google Scholar
• Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin. Microbiol. Infect. 2014;20:42–48.
   PubMed Web of Science ®Google Scholar
• Lempers VJC, Martial LC, Schreuder MF, et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Current Opinion in Pharmacology. 2015;24:38–44.
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the british society for medical mycology. Journal of Antimicrobial Chemotherapy. 2014;69:1162–1176.
   PubMed Web of Science ®Google Scholar
• Chau MM, Kong DCM, Van Hal SJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern. Med. J. 2014;44:1364–1388.
   PubMed Web of Science ®Google Scholar
• Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Therapeutic Drug Monitoring. 2008;30:167–172.
   PubMed Web of Science ®Google Scholar
• Jancel T, Shaw PA, Hallahan CW, et al. Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J. Clin. Pharm. Ther. 2017;42:75–79.
   PubMed Web of Science ®Google Scholar
• Vicenzi EB, Calore E, Decembrino N, et al. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur. J. Haematol. 2017. DOI:10.1111/ejh.13017.
   Web of Science ®Google Scholar
• Katragkou A, Tsikopoulou F, Roilides E, et al. Posaconazole: when and how? The clinician’s view. Mycoses. 2012;55:110–122.
   PubMed Web of Science ®Google Scholar
• EMA Noxafil(R) profile. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000610/WC500037785.pdf. ( Accessed 2018 January 25)
   Google Scholar
• Dekkers BGJ, Bakker M, Van Der Elst KCM, et al. Therapeutic drug monitoring of posaconazole: an update. Curr. Fungal Infect. Rep. 2016;10:51–61.
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrobial Agents and Chemotherapy. 2006;50:2009–2015.
   PubMed Web of Science ®Google Scholar
• Pfaller M, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagnostic Microbiology and Infectious Disease. 2004;48:201–205.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. Journal of Clinical Microbiology. 2003;41:3623–3626.
   PubMed Web of Science ®Google Scholar
• Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. Journal of Antimicrobial Chemotherapy. 2003;53:74–80.
   PubMed Web of Science ®Google Scholar
• Mann PA, McNicholas PM, Chau AS, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of candida species. Antimicrobial Agents and Chemotherapy. 2009;53:5026–5034.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335–47 (2007).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348–59 (2007).
   PubMed Web of Science ®Google Scholar
• Döring M, Müller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect. Dis. 12, 263 (2012).
   PubMed Web of Science ®Google Scholar
• Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur. J. Clin. Microbiol. Infect. Dis. 2014;33:629–638.
   PubMed Web of Science ®Google Scholar
• Döring M, Eikemeier M, Cabanillas Stanchi KM, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1189–1200 (2015).
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Med. Mycol. 2017;55:375–384.
   PubMed Web of Science ®Google Scholar
• Lewis R, Bruggerman R, Padoin C, et al. Triazole antifungal therapeutic drug monitoring. ECIL 6 meeting. Available at: http://www.ecil-leukaemia.com/telechargements2015/ECIL6-Triazole-TDM-07-12-2015-Lewis-R-et-al.pdf (Accessed 2017 September 9)
   Google Scholar
• Campoli P, Perlin DS, Kristof AS, et al. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. The Journal of Infectious Diseases. 2013;208:1717–1728.
   PubMed Web of Science ®Google Scholar
• Pagano L, Verga L, Busca A, et al. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. Journal of Antimicrobial Chemotherapy. 2014;69:3142–3147.
   PubMed Web of Science ®Google Scholar
• De La Serna J, Jarque I, López-Jiménez J, et al. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. Rev. Esp. Quimioter. 2013;26:64–69.
   PubMed Web of Science ®Google Scholar
• Mathew S, Kussin ML, Liu D, et al. Retrospective analysis of posaconazole suspension dosing strategies in a pediatric oncology population: single-center experience. Journal of the Pediatric Infectious Diseases Society. 2017;6:e149–e151.
   PubMed Web of Science ®Google Scholar
• McMahon J, Théorêt Y, Autmizguine J, et al. Posaconazole plasma monitoring in immunocompromised children. Journal of the Pediatric Infectious Diseases Society. 2017;6:389–392.
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas Stanchi KM, et al. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Med. Mycol 2017;55:91.
   Web of Science ®Google Scholar
• Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey Eur. J. Clin. Microbiol. Infect. Dis. 2010;29:1043–1045.
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases 2002;34:563–571.
   PubMed Web of Science ®Google Scholar
• Bernardo V, Cross SJ, Crews KR, et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer Ann Pharmacother 2013;47:976–983.
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrobial Agents and Chemotherapy 2009;53:958–966.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 2007;44:2–12.
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrobial Agents and Chemotherapy. 2007;51:812–818.
   PubMed Web of Science ®Google Scholar
• Gwee A, Cranswick N, Curtis NP. The pediatric infectious disease journal. Posaconazole. 2015;34:604–606.
   Google Scholar
• Heinz WJ, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Medical Mycology 2016;54:128–137.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area. The Pediatric Infectious Disease Journal. 2016;35:183–188.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version4.0. (2009). Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. (Accessed 2017 September 9)
   Google Scholar
• Alavi S, Ebadi M. Prolonged vincristine toxicity induced by concurrent posaconazole in a child with T-cell acute lymphoblastic leukemia. Iran. J. Med. Sci. 2013;38:135–136.
   PubMedGoogle Scholar
• Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. Journal of Pediatric Hematology/Oncology. 2009;31:292–295.
   PubMed Web of Science ®Google Scholar
• Hamdy DA, El-Geed H, El-Salem S, et al. Posaconazole-vincristine coadministration triggers seizure in a young female adult: a case report. Case Rep. Hematol. 2012;2012:343742.
   PubMedGoogle Scholar
• Pekpak E, İleri T, İnce E, et al. Toxicity of vincristine combined with posaconazole in children with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 2017;1. DOI:10.1097/MPH.0000000000001022.
   Google Scholar
• Soysal A. Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infection and Drug Resistance. 2015;8:321–331.
   PubMed Web of Science ®Google Scholar
• Cámara R, Gozalbo I, Jurado M, et al. Cost-effectiveness of posaconazole tablets for invasive fungal infections prevention in acute myelogenous leukemia or myelodysplastic syndrome patients in spain. Adv. Ther. 2017;34:2104–2119.
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas Stanchi KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J. Cancer Res. Clin. Oncol. 2017;143:1281–1292.
   PubMed Web of Science ®Google Scholar